$VNDA
Vanda Pharmaceuticals Inc.

2017 Q4 Form 10-K Financial Statement

#000119312518046425 Filed on February 15, 2018

View on sec.gov

Income Statement

Concept 2017 Q4 2017 2016 Q4
Revenue $44.28M $165.1M $38.24M
YoY Change 15.77% 13.06% 20.08%
Cost Of Revenue $4.790M $17.85M $5.270M
YoY Change -9.11% -27.78% -14.59%
Gross Profit $39.05M $147.2M $30.87M
YoY Change 26.52% 21.38% 35.77%
Gross Profit Margin 88.2% 89.19% 80.71%
Selling, General & Admin $31.05M $123.8M $23.91M
YoY Change 29.86% 24.11% -17.21%
% of Gross Profit 79.51% 84.11% 77.46%
Research & Development $10.15M $38.55M $7.610M
YoY Change 33.38% 32.21% -13.03%
% of Gross Profit 25.99% 26.18% 24.65%
Depreciation & Amortization $800.0K $1.200M $2.300M
YoY Change -65.22% 33.33% -28.13%
% of Gross Profit 2.05% 0.82% 7.45%
Operating Expenses $41.64M $162.4M $33.63M
YoY Change 23.82% 25.94% -17.11%
Operating Profit -$2.150M -$16.90M -$654.0K
YoY Change 228.75% -8.98% -95.61%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $400.0K $1.500M $150.0K
YoY Change 166.67% 114.29% 50.0%
Pretax Income -$1.750M -$15.69M -$500.0K
YoY Change 250.0% -13.3% -96.62%
Income Tax $90.00K $136.0K $100.0K
% Of Pretax Income
Net Earnings -$1.838M -$15.57M -$604.0K
YoY Change 204.3% -13.56% -95.92%
Net Earnings / Revenue -4.15% -9.43% -1.58%
Basic Earnings Per Share -$0.35
Diluted Earnings Per Share -$40.95K -$0.35 -$13.65K
COMMON SHARES
Basic Shares Outstanding 44.93M shares 44.74M shares 43.95M shares
Diluted Shares Outstanding 44.74M shares

Balance Sheet

Concept 2017 Q4 2017 2016 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $143.4M $143.4M $141.3M
YoY Change 1.47% 1.49% -1.29%
Cash & Equivalents $33.63M $33.60M $40.43M
Short-Term Investments $109.8M $109.8M $100.9M
Other Short-Term Assets $2.712M $8.000M $1.579M
YoY Change 71.75% -32.2% 61.29%
Inventory $840.0K $800.0K $779.0K
Prepaid Expenses
Receivables $17.60M $17.60M $20.27M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $169.9M $169.9M $174.2M
YoY Change -2.48% -2.47% 4.58%
LONG-TERM ASSETS
Property, Plant & Equipment $5.306M $5.300M $5.015M
YoY Change 5.8% 6.0% 9.74%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $4.200M $4.200M $3.400M
YoY Change 23.53% 23.53% 6.25%
Total Long-Term Assets $35.57M $35.50M $36.20M
YoY Change -1.74% -1.93% -22.16%
TOTAL ASSETS
Total Short-Term Assets $169.9M $169.9M $174.2M
Total Long-Term Assets $35.57M $35.50M $36.20M
Total Assets $205.4M $205.4M $210.4M
YoY Change -2.35% -2.38% -1.26%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.400M $4.400M $4.600M
YoY Change -4.35% -4.35% -13.21%
Accrued Expenses $39.00M $39.00M $45.80M
YoY Change -14.85% -14.85% -0.43%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $70.36M $70.40M $50.32M
YoY Change 39.83% 39.96% -1.94%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $3.675M $3.700M $3.724M
YoY Change -1.32% -87.11% 0.49%
Total Long-Term Liabilities $3.675M $3.700M $3.724M
YoY Change -1.32% -87.11% 0.49%
TOTAL LIABILITIES
Total Short-Term Liabilities $70.36M $70.40M $50.32M
Total Long-Term Liabilities $3.675M $3.700M $3.724M
Total Liabilities $74.04M $74.00M $79.04M
YoY Change -6.33% -6.33% -1.22%
SHAREHOLDERS EQUITY
Retained Earnings -$361.4M -$345.9M
YoY Change 4.5% 5.49%
Common Stock $492.8M $477.1M
YoY Change 3.29% 3.54%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $131.4M $131.4M $131.3M
YoY Change
Total Liabilities & Shareholders Equity $205.4M $205.4M $210.4M
YoY Change -2.35% -2.38% -1.26%

Cashflow Statement

Concept 2017 Q4 2017 2016 Q4
OPERATING ACTIVITIES
Net Income -$1.838M -$15.57M -$604.0K
YoY Change 204.3% -13.56% -95.92%
Depreciation, Depletion And Amortization $800.0K $1.200M $2.300M
YoY Change -65.22% 33.33% -28.13%
Cash From Operating Activities $3.400M -$1.983M -$1.200M
YoY Change -383.33% -75.52% 200.0%
INVESTING ACTIVITIES
Capital Expenditures -$200.0K $1.664M -$700.0K
YoY Change -71.43% 18.27% 0.0%
Acquisitions
YoY Change
Other Investing Activities $7.500M -$124.0K $8.800M
YoY Change -14.77% -369.57% 72.55%
Cash From Investing Activities $7.400M -$10.23M $8.200M
YoY Change -9.76% 2.31% 86.36%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 100.0K $5.251M 800.0K
YoY Change -87.5% -32.68%
NET CHANGE
Cash From Operating Activities 3.400M -$1.983M -1.200M
Cash From Investing Activities 7.400M -$10.23M 8.200M
Cash From Financing Activities 100.0K $5.251M 800.0K
Net Change In Cash 10.90M -$6.921M 7.800M
YoY Change 39.74% -33.27% 95.0%
FREE CASH FLOW
Cash From Operating Activities $3.400M -$1.983M -$1.200M
Capital Expenditures -$200.0K $1.664M -$700.0K
Free Cash Flow $3.600M -$3.647M -$500.0K
YoY Change -820.0% -61.64% -266.67%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
45437938 shares
CY2017Q2 dei Entity Public Float
EntityPublicFloat
715200000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
160817000
CY2014Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
128890000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
60901000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
133027000
CY2015Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
139037000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
50843000
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
44000614 shares
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
44000614 shares
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-345859000
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3724000
CY2016Q4 us-gaap Liabilities
Liabilities
79044000
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
210374000
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4291000
CY2016Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
666000
CY2016Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
666000
CY2016Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
16196000
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
-1000
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
58000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
131330000
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
44000
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
477087000
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
59000
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3231000
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3192000
CY2016Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
33122000
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1134000
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
50320000
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
146012000
CY2016Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
4555000
CY2016Q4 us-gaap Assets Current
AssetsCurrent
174175000
CY2016Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
100914000
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
12443000
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
2558000
CY2016Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
17000
CY2016Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1579000
CY2016Q4 us-gaap Prepaid Royalties
PrepaidRoyalties
1761000
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5015000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
40426000
CY2016Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
100000
CY2016Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
2435000
CY2016Q4 us-gaap Inventory Net
InventoryNet
779000
CY2016Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
20268000
CY2016Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
100914000
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
84177000
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8246000
CY2016Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
800000
CY2016Q4 us-gaap Assets
Assets
210374000
CY2016Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
5477000
CY2016Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
146778000
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Other
DeferredTaxAssetsTaxDeferredExpenseOther
1019000
CY2016Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
27819000
CY2016Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
60941000
CY2016Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
762000
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
11788000
CY2016Q4 vnda Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
2397000
CY2016Q4 vnda Deferred Tax Assets Liabilities Before Valuation Allowance Net
DeferredTaxAssetsLiabilitiesBeforeValuationAllowanceNet
146112000
CY2016Q4 vnda Inventory Raw Materials Net Of Reserves Non Current
InventoryRawMaterialsNetOfReservesNonCurrent
127000
CY2016Q4 vnda Inventory Finished Goods Net Of Reserves Non Current
InventoryFinishedGoodsNetOfReservesNonCurrent
83000
CY2016Q4 vnda Accrued Government And Other Rebates Current
AccruedGovernmentAndOtherRebatesCurrent
34124000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
70363000
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
116110000
CY2016Q4 vnda Accrued Research And Development Expense
AccruedResearchAndDevelopmentExpense
3024000
CY2016Q4 vnda Inventory Work In Process Net Of Reserves Non Current
InventoryWorkInProcessNetOfReservesNonCurrent
2225000
CY2016Q4 vnda Deferred Tax Assets Tax Credit Carryforwards Research And Other
DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther
41104000
CY2016Q4 vnda Prepaid Consulting And Professional Fees Current
PrepaidConsultingAndProfessionalFeesCurrent
6051000
CY2016Q4 vnda Inventory And Other Non Current
InventoryAndOtherNonCurrent
3365000
CY2016Q4 vnda Milestone Obligation Under License Agreement Noncurrent
MilestoneObligationUnderLicenseAgreementNoncurrent
25000000
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
44938133 shares
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
44938133 shares
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-361426000
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3675000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
19789000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
2295000
CY2017Q4 us-gaap Liabilities
Liabilities
74038000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
205425000
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5323000
CY2017Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
-386000
CY2017Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
386000
CY2017Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
20335000
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
29000
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-34000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
131387000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
2174000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
2311000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
2187000
CY2017Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
29000
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
45000
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
492802000
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-63000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4480000
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3961000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
2351000
CY2017Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
34872000
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1994000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
8471000
CY2017Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
4394000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
169857000
CY2017Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
109786000
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
59222000
CY2017Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
113782000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
5383000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
1967000
CY2017Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
80000
CY2017Q4 us-gaap Other Assets Current
OtherAssetsCurrent
2712000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5306000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
33627000
CY2017Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
3316000
CY2017Q4 us-gaap Inventory Net
InventoryNet
840000
CY2017Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
17601000
CY2017Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
9000000
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9786000
CY2017Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
700000
CY2017Q4 us-gaap Assets
Assets
205425000
CY2017Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
3745000
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
116467000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Other
DeferredTaxAssetsTaxDeferredExpenseOther
2174000
CY2017Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
26069000
CY2017Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
60941000
CY2017Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
760000
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8003000
CY2017Q4 vnda Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
2415000
CY2017Q4 vnda Deferred Tax Assets Liabilities Before Valuation Allowance Net
DeferredTaxAssetsLiabilitiesBeforeValuationAllowanceNet
116081000
CY2017Q4 vnda Inventory Raw Materials Net Of Reserves Non Current
InventoryRawMaterialsNetOfReservesNonCurrent
87000
CY2017Q4 vnda Inventory Finished Goods Net Of Reserves Non Current
InventoryFinishedGoodsNetOfReservesNonCurrent
408000
CY2017Q4 vnda Accrued Government And Other Rebates Current
AccruedGovernmentAndOtherRebatesCurrent
23028000
CY2017Q4 vnda Accrued Research And Development Expense
AccruedResearchAndDevelopmentExpense
4663000
CY2017Q4 vnda Milestone Obligation Under License Agreement Current
MilestoneObligationUnderLicenseAgreementCurrent
27000000
CY2017Q4 vnda Inventory Work In Process Net Of Reserves Non Current
InventoryWorkInProcessNetOfReservesNonCurrent
2821000
CY2017Q4 vnda Deferred Tax Assets Tax Credit Carryforwards Research And Other
DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther
43976000
CY2017Q4 vnda Prepaid Consulting And Professional Fees Current
PrepaidConsultingAndProfessionalFeesCurrent
2876000
CY2017Q4 vnda Inventory And Other Non Current
InventoryAndOtherNonCurrent
4193000
CY2015 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5660199 shares
CY2015 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.94
CY2015 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.350 pure
CY2015 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.254 pure
CY2015 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.051 pure
CY2015 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.015 pure
CY2015 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
12449000
CY2015 us-gaap Advertising Expense
AdvertisingExpense
3400000
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y0M0D
CY2015 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42250254 shares
CY2015 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42250254 shares
CY2015 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
-0.001 pure
CY2015 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.001 pure
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0167 pure
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.59
CY2015 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
42250254 shares
CY2015 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.94
CY2015 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.003 pure
CY2015 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.057 pure
CY2015 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000 pure
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.60 pure
CY2015 us-gaap Revenues
Revenues
109925000
CY2015 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2527000
CY2015 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
23000
CY2015 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-677000
CY2015 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
4374000
CY2015 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
109925000
CY2015 us-gaap Other Income
OtherIncome
320000
CY2015 us-gaap Operating Income Loss
OperatingIncomeLoss
-40185000
CY2015 us-gaap Net Income Loss
NetIncomeLoss
-39865000
CY2015 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-387000
CY2015 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
12677000
CY2015 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-39842000
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7961000
CY2015 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
283000
CY2015 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
193111000
CY2015 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-483000
CY2015 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
23000
CY2015 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2558000
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-39865000
CY2015 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7961000
CY2015 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0
CY2015 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0
CY2015 us-gaap Depreciation
Depreciation
582000
CY2015 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-26598000
CY2015 us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
999000
CY2015 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
168041000
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
7961000
CY2015 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
283000
CY2015 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2015 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
300000
CY2015 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
84531000
CY2015 us-gaap Cost Of Goods Sold Excluding Depreciation Depletion And Amortization
CostOfGoodsSoldExcludingDepreciationDepletionAndAmortization
23462000
CY2015 us-gaap Costs And Expenses
CostsAndExpenses
150110000
CY2015 us-gaap Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
9432000
CY2015 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
1900000
CY2015 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
4091000
CY2015 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
200000
CY2015 us-gaap Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1
NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
25000000
CY2015 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
29145000
CY2015 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
12972000
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-10058000
CY2015 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
0
CY2015 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4374000
CY2015 vnda Deferred Tax Assets Valuation Allowance Decrease
DeferredTaxAssetsValuationAllowanceDecrease
6855000
CY2015 vnda Deferred Tax Assets Valuation Allowance Increase
DeferredTaxAssetsValuationAllowanceIncrease
17002000
CY2015 vnda Increase Decrease In Accrued Government And Other Rebates
IncreaseDecreaseInAccruedGovernmentAndOtherRebates
35055000
CY2015 vnda Effective Income Tax Rate Reconciliation Tax Credits Orphan Drug
EffectiveIncomeTaxRateReconciliationTaxCreditsOrphanDrug
0.016 pure
CY2015 vnda Effective Income Tax Rate Reconciliation Effective Tax Rate Adjustment
EffectiveIncomeTaxRateReconciliationEffectiveTaxRateAdjustment
-0.014 pure
CY2015 vnda Effective Income Tax Rate Reconciliation Tax Cuts And Job Act Rate
EffectiveIncomeTaxRateReconciliationTaxCutsAndJobActRate
0.000 pure
CY2015 vnda Effective Income Tax Rate Reconciliation Tax Cuts And Job Act Of2017 Change In Valuation Allowance
EffectiveIncomeTaxRateReconciliationTaxCutsAndJobActOf2017ChangeInValuationAllowance
0.000 pure
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3136515 shares
CY2017 dei Amendment Flag
AmendmentFlag
false
CY2017 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
0.06 pure
CY2017 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2017 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
CY2017 dei Document Type
DocumentType
10-K
CY2017 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.35
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.350 pure
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.478 pure
CY2017 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.130 pure
CY2017 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.090 pure
CY2017 dei Entity Central Index Key
EntityCentralIndexKey
0001347178
CY2017 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2017 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-1983000
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M21D
CY2017 dei Trading Symbol
TradingSymbol
VNDA
CY2017 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44735146 shares
CY2017 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44735146 shares
CY2017 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 18pt"> <b><i>Concentrations of Credit Risk</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash, cash equivalents and marketable securities. The Company places its cash, cash equivalents and marketable securities with highly-rated financial institutions. At December&#xA0;31, 2017, the Company maintained all of its cash, cash equivalents and marketable securities in three financial institutions. Deposits held with these institutions may exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand, and the Company believes there is minimal risk of losses on such balances.</p> </div>
CY2017 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
-0.027 pure
CY2017 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.017 pure
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0197 pure
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
7.81
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
44735146 shares
CY2017 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2017 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.50 pure
CY2017 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.35
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.026 pure
CY2017 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.081 pure
CY2017 us-gaap Revenues
Revenues
165083000
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1664000
CY2017 dei Document Period End Date
DocumentPeriodEndDate
2017-12-31
CY2017 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2017 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2017 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
30000
CY2017 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 Segment
CY2017 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
-122000
CY2017 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
426000
CY2017 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
5251000
CY2017 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
165083000
CY2017 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-124000
CY2017 us-gaap Other Income
OtherIncome
1472000
CY2017 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"> <b><i>Use of Estimates</i></b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates that affect the reported amounts of assets and liabilities at the date of the financial statements, disclosure of contingent assets and liabilities, and the reported amounts of revenue and expenses during the reporting period. Management continually <font style="white-space:nowrap">re-evaluates</font> its estimates, judgments and assumptions, and management&#x2019;s evaluation could change. Actual results could differ from those estimates.</p> </div>
CY2017 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.009 pure
CY2017 dei Entity Registrant Name
EntityRegistrantName
Vanda Pharmaceuticals Inc.
CY2017 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-16903000
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.57 pure
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-15567000
CY2017 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1060000
CY2017 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2525000
CY2017 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15659000
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10465000
CY2017 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
148135000
CY2017 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-587000
CY2017 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-92000
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3652000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
300000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-15431000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-15700000
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10465000
CY2017 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0
CY2017 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0
CY2017 us-gaap Depreciation
Depreciation
1234000
CY2017 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
40000
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
136000
CY2017 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-10107000
CY2017 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
139568000
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
10465000
CY2017 us-gaap Advertising Expense
AdvertisingExpense
1300000
CY2017 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2017 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
-66000
CY2017 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
800000
CY2017 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
123841000
CY2017 us-gaap Cost Of Goods Sold Excluding Depreciation Depletion And Amortization
CostOfGoodsSoldExcludingDepreciationDepletionAndAmortization
17848000
CY2017 us-gaap Costs And Expenses
CostsAndExpenses
181986000
CY2017 us-gaap Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
5953000
CY2017 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
3200000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
5251000
CY2017 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
0
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
38547000
CY2017 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1750000
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-6799000
CY2017 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
65000
CY2017 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
137000
CY2017 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
0
CY2017 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5251000
CY2017 vnda Share Based Compensation Arrangement By Share Based Payment Annual Award Vesting Period Directors
ShareBasedCompensationArrangementByShareBasedPaymentAnnualAwardVestingPeriodDirectors
P1Y
CY2017 vnda Defined Contribution Plan Vesting Period
DefinedContributionPlanVestingPeriod
P4Y
CY2017 vnda Deferred Tax Assets Valuation Allowance Decrease
DeferredTaxAssetsValuationAllowanceDecrease
42305000
CY2016 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-62000
CY2016 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
7751000
CY2016 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
146017000
CY2016 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
46000
CY2016 us-gaap Other Income
OtherIncome
665000
CY2017 vnda Deferred Tax Assets Valuation Allowance Increase
DeferredTaxAssetsValuationAllowanceIncrease
12403000
CY2017 vnda Percentage Of Responsibility For Patients Cost Of Branded Prescription Under Medicare Part D
PercentageOfResponsibilityForPatientsCostOfBrandedPrescriptionUnderMedicarePartD
0.50 pure
CY2017 vnda Option Awards Vesting Period After Completion Of One Year Of Service
OptionAwardsVestingPeriodAfterCompletionOfOneYearOfService
P3Y
CY2017 vnda Increase Decrease In Accrued Government And Other Rebates
IncreaseDecreaseInAccruedGovernmentAndOtherRebates
-11096000
CY2017 vnda Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Share Subject To Option Awards
ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfShareSubjectToOptionAwards
0.25 pure
CY2017 vnda Share Based Compensation Option Awards Contractual Term
ShareBasedCompensationOptionAwardsContractualTerm
P10Y
CY2017 vnda Effective Income Tax Rate Reconciliation Tax Credits Orphan Drug
EffectiveIncomeTaxRateReconciliationTaxCreditsOrphanDrug
0.063 pure
CY2017 vnda Percentage Of Future Sublicense Fees Payable
PercentageOfFutureSublicenseFeesPayable
Mid-twenties
CY2017 vnda Share Based Compensation Arrangement By Share Based Payment Award Remaining Percentage Of Share Subject To Option Awards
ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingPercentageOfShareSubjectToOptionAwards
0.75 pure
CY2017 vnda Operating Loss Carryforwards Beginning Expiration Year
OperatingLossCarryforwardsBeginningExpirationYear
2028
CY2017 vnda Effective Income Tax Rate Reconciliation Effective Tax Rate Adjustment
EffectiveIncomeTaxRateReconciliationEffectiveTaxRateAdjustment
0.051 pure
CY2017 vnda Share Based Compensation Arrangement By Share Based Payment Award Initial Vesting Period Directors
ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialVestingPeriodDirectors
P4Y
CY2017 vnda Effective Income Tax Rate Reconciliation Tax Cuts And Job Act Rate
EffectiveIncomeTaxRateReconciliationTaxCutsAndJobActRate
-2.626 pure
CY2017 vnda Percentage At Which Certain Federal Deferred Tax Assets And Liabilities Remeasured
PercentageAtWhichCertainFederalDeferredTaxAssetsAndLiabilitiesRemeasured
0.21 pure
CY2017 vnda Effective Income Tax Rate Reconciliation Tax Cuts And Job Act Of2017 Change In Valuation Allowance
EffectiveIncomeTaxRateReconciliationTaxCutsAndJobActOf2017ChangeInValuationAllowance
2.626 pure
CY2017 vnda Orphan Drug Credit Beginning Expiration Year
OrphanDrugCreditBeginningExpirationYear
2030
CY2017 vnda Research And Development Credit Beginning Expiration Year
ResearchAndDevelopmentCreditBeginningExpirationYear
2024
CY2016 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4943797 shares
CY2016 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.41
CY2016 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.350 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.384 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.125 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.038 pure
CY2016 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-8103000
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y0M29D
CY2016 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
43449441 shares
CY2016 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43449441 shares
CY2016 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
-0.008 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.008 pure
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0137 pure
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.53
CY2016 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
43449441 shares
CY2016 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.41
CY2016 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.039 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.000 pure
CY2016 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.006 pure
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.57 pure
CY2016 us-gaap Revenues
Revenues
146017000
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1407000
CY2016 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
-1000
CY2016 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
20000
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
6159000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
200000
CY2016 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-542000
CY2016 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
19000
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
-18571000
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-18010000
CY2016 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-200000
CY2016 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
4298000
CY2016 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-17991000
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8543000
CY2016 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
165405000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-17906000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-18100000
CY2016 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8543000
CY2016 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0
CY2016 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0
CY2016 us-gaap Depreciation
Depreciation
935000
CY2016 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
6000
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
104000
CY2016 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-10071000
CY2016 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
156787000
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
8543000
CY2016 us-gaap Advertising Expense
AdvertisingExpense
1400000
CY2016 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2016 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
142000
CY2016 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
400000
CY2016 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
99787000
CY2016 us-gaap Cost Of Goods Sold Excluding Depreciation Depletion And Amortization
CostOfGoodsSoldExcludingDepreciationDepletionAndAmortization
24712000
CY2016 us-gaap Costs And Expenses
CostsAndExpenses
164588000
CY2016 us-gaap Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
575000
CY2016 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
2500000
CY2016 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
7751000
CY2016 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
200000
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
29156000
CY2016 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
10933000
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-10417000
CY2016 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
66000
CY2016 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
-104000
CY2016 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
0
CY2016 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
7751000
CY2016 vnda Deferred Tax Assets Valuation Allowance Decrease
DeferredTaxAssetsValuationAllowanceDecrease
4056000
CY2016 vnda Deferred Tax Assets Valuation Allowance Increase
DeferredTaxAssetsValuationAllowanceIncrease
11031000
CY2017Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-2150000
CY2017Q4 us-gaap Net Income Loss
NetIncomeLoss
-1838000
CY2016 vnda Increase Decrease In Accrued Government And Other Rebates
IncreaseDecreaseInAccruedGovernmentAndOtherRebates
-1426000
CY2016 vnda Effective Income Tax Rate Reconciliation Tax Credits Orphan Drug
EffectiveIncomeTaxRateReconciliationTaxCreditsOrphanDrug
0.076 pure
CY2016 vnda Effective Income Tax Rate Reconciliation Effective Tax Rate Adjustment
EffectiveIncomeTaxRateReconciliationEffectiveTaxRateAdjustment
0.000 pure
CY2016 vnda Effective Income Tax Rate Reconciliation Tax Cuts And Job Act Rate
EffectiveIncomeTaxRateReconciliationTaxCutsAndJobActRate
0.000 pure
CY2016 vnda Effective Income Tax Rate Reconciliation Tax Cuts And Job Act Of2017 Change In Valuation Allowance
EffectiveIncomeTaxRateReconciliationTaxCutsAndJobActOf2017ChangeInValuationAllowance
0.000 pure
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.17
CY2017Q1 us-gaap Revenues
Revenues
37415000
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-7906000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-7645000
CY2017Q1 us-gaap Gross Profit
GrossProfit
32958000
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.29
CY2016Q1 us-gaap Revenues
Revenues
33262000
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-12475000
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-12358000
CY2016Q1 us-gaap Gross Profit
GrossProfit
24363000
CY2016Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.11
CY2016Q2 us-gaap Revenues
Revenues
36029000
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4789000
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-4618000
CY2016Q2 us-gaap Gross Profit
GrossProfit
26593000
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.03
CY2017Q2 us-gaap Revenues
Revenues
42056000
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1924000
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-1534000
CY2017Q2 us-gaap Gross Profit
GrossProfit
37095000
CY2016Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
CY2016Q3 us-gaap Revenues
Revenues
38482000
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-653000
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-430000
CY2016Q3 us-gaap Gross Profit
GrossProfit
28549000
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.10
CY2017Q3 us-gaap Revenues
Revenues
41336000
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4923000
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-4550000
CY2017Q3 us-gaap Gross Profit
GrossProfit
36379000
CY2016Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
CY2016Q4 us-gaap Revenues
Revenues
38244000
CY2016Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-654000
CY2016Q4 us-gaap Net Income Loss
NetIncomeLoss
-604000
CY2016Q4 us-gaap Gross Profit
GrossProfit
30867000
CY2017Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.04
CY2017Q4 us-gaap Revenues
Revenues
44276000
CY2017Q4 us-gaap Gross Profit
GrossProfit
39053000

Files In Submission

Name View Source Status
0001193125-18-046425-index-headers.html Edgar Link pending
0001193125-18-046425-index.html Edgar Link pending
0001193125-18-046425.txt Edgar Link pending
0001193125-18-046425-xbrl.zip Edgar Link pending
d503767d10k.htm Edgar Link pending
d503767dex1037.htm Edgar Link pending
d503767dex231.htm Edgar Link pending
d503767dex311.htm Edgar Link pending
d503767dex312.htm Edgar Link pending
d503767dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g503767g08s72.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vnda-20171231.xml Edgar Link completed
vnda-20171231.xsd Edgar Link pending
vnda-20171231_cal.xml Edgar Link unprocessable
vnda-20171231_def.xml Edgar Link unprocessable
vnda-20171231_lab.xml Edgar Link unprocessable
vnda-20171231_pre.xml Edgar Link unprocessable